Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fluidigm Announces Unrestricted Sales into Prenatal Health

Published: Tuesday, June 19, 2012
Last Updated: Tuesday, June 19, 2012
Bookmark and Share
Fluidigm collaboration ends.

Fluidigm Corporation has announced that it can now offer unrestricted sales of its digital PCR and other advanced technology to customers interested in pursuing research and product development into the prenatal health and non-invasive prenatal diagnostics fields, as well as other fields.

This enhanced freedom to operate comes as a result of the ending of the collaboration agreement previously reported in the company's filings with the Securities and Exchange Commission between Fluidigm and Novartis Vaccines & Diagnostics, Inc.

Under the collaboration agreement, Fluidigm granted an exclusive option to its technology in specific areas of prenatal health and diagnostics, and Fluidigm could not sell its products or services in these fields, other than in some cases for research applications.

This option has expired unexercised. Also, while the details of the collaboration remain confidential, Fluidigm can confirm that it successfully achieved all of its technical feasibility milestones in the first phase of the collaboration and, accordingly, received all milestone payments.

The re-opening of previously restricted fields of use for Fluidigm products and access to significant product enhancements represent exciting opportunities for Fluidigm's customer base.

A number of Fluidigm's customers had expressed concerns over their ability to freely operate in the fields of prenatal health and non-invasive prenatal diagnostics in view of the collaboration agreement.

Some potential customers chose to pursue alternative options because of this uncertainty.

"With the termination of this agreement, highly valuable intellectual property rights in non-invasive prenatal diagnostics and digital PCR, which had been exclusively optioned under the agreement, now revert back to Fluidigm. We are open for business without restriction in all fields," said Gajus Worthington, Fluidigm President and Chief Executive Officer.

Fluidigm can now fully pursue all market opportunities with customers interested in researching and developing products in all fields, including prenatal health and non-invasive prenatal diagnostics.

"We appreciate that there are significant market opportunities in these areas and there is substantial customer interest. We look forward to helping these customers achieve their research and development objectives," Worthington added.

With the termination of the collaboration, Fluidigm's customers may experience other, more direct benefits.

Chief among them is unrestricted access to the company's prototype 200,000-chambered digital PCR chip with associated instrumentation and software developed under several on-going collaborative efforts.

The company can now commercialize this much higher density chip, for which it has experimentally demonstrated both very high sensitivity and reproducibility.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Revealing the Role of “Precocious” Dendritic Cells in Inflammatory Response
Discovery makes it possible for researchers to explore how these “precocious” cells escalate the body’s immune response when the body is under attack.
Monday, July 07, 2014
Singapore Single-Cell Research Centre Opens Door for Asian Biological Discoveries
Centre dedicated to diagnosis and treatment derived from single-cell exploration.
Monday, April 29, 2013
Fluidigm Announces $60 Million Public Offering of Common Stock
Company has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million.
Wednesday, August 22, 2012
New Research Center to Focus on Mammalian Single Cell Genomics
New Center will feature a complete suite of Fluidigm single-cell tools, protocols and technologies.
Friday, June 15, 2012
Fluidigm Reports Financial Results for First Quarter 2012
Q1 total revenue up 26% compared to Q1 2011.
Monday, May 14, 2012
Leading Leukemia Lab Invests In Fluidigm Access Array™ and EP1™ Systems
Fluidigm Corporation has announced that MLL Munich Leukemia Laboratory (www.mll.com) has purchased Access Array™ and EP1™ Systems.
Tuesday, November 16, 2010
Research Newsletter for Biochip User Community
Fluidigm announces availability of the Fall 2010 edition of its community newsletter.
Tuesday, October 19, 2010
Fluidigm Europe Announces a new Technical Poster Describing its Access Array™ Chip Technology
New poster describes how Access Array™ chip technology has been used at NCI’s core facility to capture and sequence the entire EBV genome.
Friday, August 13, 2010
Modelling the Genetic Circuitry of Cell-to-Cell Communication
Stanford researchers used Fluidigm support instrumentation for analysis and modeling on how biological systems operate at the cellular level.
Thursday, July 15, 2010
Fluidigm Announces Availability of its Summer 2010 Edition of ‘IFC Application Hotspot’ E-newsletter
Issue includes two customer application studies, a recorded video interview with the GIS and a new single-cell gene expression protocol.
Friday, July 09, 2010
Fred Walder Joins Fluidigm as Chief Business Officer
Senior Executive from Fortune 500 company to lead business development and marketing for integrated fluidic circuit inventor.
Wednesday, June 30, 2010
Pathway-Focused Gene Expression Panels Validated for Real-time PCR
Fluidigm and SABiosciences team up to create gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System.
Thursday, April 08, 2010
Fluidigm and Bayer Cropscience Enter Global Agreement for Marker-Assisted Breeding and Quality Control
Fluidigm to supply integrated fluidic circuits and instrumentation to Bayer CropScience's global operations under the multi-year agreement.
Friday, February 19, 2010
Fluidigm and Bayer Cropscience Enter Global Agreement for Marker-Assisted Breeding and Quality Control
Multi-Year Supply Agreement to Drive High-Quality Seed Supply
Thursday, January 28, 2010
USDA Purchases Fluidigm Solution for Development and Validation Testing of Cattle SNP Panels
Fluidigm’s EP1™ System will develop and validate focused 96- and 384-SNP panels for testing America’s dairy and beef cattle.
Friday, January 08, 2010
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Device May Detect Urinary Tract Infections Faster
A Lab-on-a-Disc platform developed by a German and Irish team of researchers dramatically cut the time to detect bacterial species that cause urinary tract infections -- a major cause of sepsis.
Automation Abound at AACC in Atlanta
Discover the latest breakthroughs, trends and products from the AACC Annual Meeting & Clinical Lab Expo.
Real-Time Data for Cancer Therapy
Biochemical sensor implanted at initial biopsy could allow doctors to better monitor and adjust cancer treatments.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Futuristic Brain Probe Allows for Wireless Control of Neurons
NIH-funded scientists developed an ultra-thin, minimally invasive device for controlling brain cells with drugs and light.
Microfluidic Device Mixes And Matches DNA For Synthetic Biology
Researchers have developed a microfluidic device that quickly builds packages of DNA and delivers them into bacteria or yeast for further testing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!